These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30939743)

  • 1. Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches.
    Li W; Sun Z
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30939743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
    Stengel KR; Hiebert SW
    Antioxid Redox Signal; 2015 Jul; 23(1):51-65. PubMed ID: 24730655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases as targets for multiple diseases.
    Sangshetti JN; Sakle NS; Dehghan MH; Shinde DB
    Mini Rev Med Chem; 2013 Jun; 13(7):1005-26. PubMed ID: 22876951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
    Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
    Toussirot E; Khan KA; Bertolini E; Wendling D; Herbein G
    Joint Bone Spine; 2010 Oct; 77(5):395-8. PubMed ID: 20729120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
    Götze S; Coersmeyer M; Müller O; Sievers S
    Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
    Li Y; Wang F; Chen X; Wang J; Zhao Y; Li Y; He B
    Curr Top Med Chem; 2019; 19(3):223-241. PubMed ID: 30674261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
    Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
    Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors promote osteoblast maturation.
    Schroeder TM; Westendorf JJ
    J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
    Huang L
    J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, characterization, and evaluation of Cd[L-proline]
    Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
    Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.
    Wawruszak A; Kalafut J; Okon E; Czapinski J; Halasa M; Przybyszewska A; Miziak P; Okla K; Rivero-Muller A; Stepulak A
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30691229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
    Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
    J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of histone deacetylase inhibitors in sarcoma.
    Tang F; Choy E; Tu C; Hornicek F; Duan Z
    Cancer Treat Rev; 2017 Sep; 59():33-45. PubMed ID: 28732326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
    Park J; Thomas S; Munster PN
    Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.